131 results on '"Papa, Sophie"'
Search Results
2. Proceedings of the inaugural Dark Genome Symposium: November 2022
3. Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products
4. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
5. Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study
6. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
7. Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
8. Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England
9. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
10. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
11. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
12. Problem Solving in Cancer Immunotherapy
13. Provision of cancer care during the COVID-19 pandemic
14. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience
15. The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports
16. Safe delivery of systemic anti‐cancer treatment for skin cancers during the COVID‐19 pandemic.
17. Immune checkpoint inhibitor‐related cholangiopathy: Novel clinicopathological description of a multi‐centre cohort.
18. A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant.
19. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.
20. Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis.
21. BRAF inhibitors and their immunological effects in malignant melanoma.
22. Papulonodular pigmented lesions in a patient with Stage IV malignant melanoma.
23. Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
24. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states
25. Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
26. 108 INFLIXIMAB TREATMENT FOR CHECKPOINT INHIBITOR INDUCED COLITIS: CLINICAL OUTCOMES FROM A MULTI-CENTRE STUDY
27. BRAF inhibitors:resistance and the promise of combination treatments for melanoma
28. One Piece of the Jigsaw for the Cancer Recovery Strategy: Prevalence of COVID-19 in Patients With Cancer.
29. Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London.
30. Setting the scene – a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
31. New Developments in Imaging Cell‐based Therapy.
32. Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells.
33. Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis.
34. Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
35. Dynamic imaging for CAR-T-cell therapy.
36. Development of PSMA-specific immunotherapy for prostate cancer with PIN4 gene-modified T cells
37. Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials.
38. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
39. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients.
40. Utilizing Immunocytokines for Cancer Therapy.
41. Engineering T cell metabolism for enhanced CAR T cell efficacy
42. Culture Matters As Well.
43. Engineering ErbB-targeted CAR T-cells to improve efficacy in treatment of solid tumours
44. Combination immunotherapy using ErbB re-targeted CAR T-cells and CRS inhibition
45. Optimising CAR T cell immunotherapy with a tumour microenvironment targeted immunocytokine
46. Reply to A. Surbone et al.
47. Chimeric antigen receptor (CAR) T-cell immunotherapy for MUC1-positive breast cancer
48. Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.
49. Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products.
50. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.